GAS6 and non-small cell lung carcinoma: Another study investigating the impact of AXL on EGFR‐TKI efficacy has shown that activation of AXL was associated with poor outcome of EGFR‐TKIs.24 However, we did not detect a tendency for OS or PFS to be shorter in EGFR‐mutated NSCLC patients with high levels of AXL or GAS6 in pretreatment tissue or plasma specimens.